Interleukin-1 blockade may interfere with immune response to infections. Treatment with medications that work through inhibition of IL-1 has been associated with an increased risk of serious infections.
- TRADE NAME: Ilaris (Novartis)
- INDICATIONS: Periodic fever syndromes, systemic juvenile idiopathic arthritis
- CLASS: Interleukin-1 inhibitor, Monoclonal antibody
- HALF-LIFE: 26 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cytochrome P450, IL-1 Blockers, Lenalidomide, TNF-Blockers
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of canakinumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/18/2023
